Related Experiment Video
Updated: Jun 8, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
38.9K
Psoriasis Risk With Immune Checkpoint Inhibitors
Sheng-Yin To1,2,3, Cho-Hao Lee4, Yi-Hsien Chen5
1Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
JAMA Dermatology
|November 6, 2024
Summary
Patients receiving immune checkpoint inhibitors (ICIs) for cancer showed a significantly increased risk of developing psoriasis. Healthcare providers should monitor for this immune-related adverse event during cancer treatment.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Immune checkpoint inhibitors (ICIs) are effective cancer therapies.
- ICIs can cause immune-related adverse events, including autoimmune conditions.
Purpose of the Study:
- To investigate the risk of psoriasis development in cancer patients treated with ICIs.
- To compare psoriasis incidence between ICI users and non-ICI users.
Main Methods:
- Nationwide cohort study using Taiwan National Health Insurance and Cancer Registry data.
- Target trial emulation design with 135,230 cancer patients (stages III-IV).
- Inverse probability of treatment weighting and Cox/Fine-Gray models used for analysis.
Main Results:
- ICI users had a higher incidence of psoriasis (5.76 per 1000 person-years) compared to non-ICI users (1.44 per 1000 person-years).
- ICI use was associated with a 2-fold increased risk of psoriasis (IPTW-adjusted HR, 3.31).
- Results were consistent across different study designs and sensitivity analyses.
Conclusions:
- Cancer patients treated with ICIs have an elevated risk of developing psoriasis.
- Awareness of this risk is crucial for clinicians managing cancer patients on immunotherapy.
- Monitoring for dermatological adverse events is important for optimal patient care.
Related Concept Videos
01:24T Cell Types and Functions
954
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
954
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:27Tumor Immunotherapy
484
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
484
01:19Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K